N/A
Manufactured by Gilead Sciences, Inc.
1,443 FDA adverse event reports analyzed
Last updated: 2026-04-15
COBICISTAT is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Gilead Sciences, Inc.. The most commonly reported adverse reactions for COBICISTAT include DRUG INTERACTION, CUSHING^S SYNDROME, FOETAL EXPOSURE DURING PREGNANCY, IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME, SEROTONIN SYNDROME. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for COBICISTAT.
Out of 603 classified reports for COBICISTAT:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 1,443 FDA FAERS reports that mention COBICISTAT. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INTERACTION, CUSHING^S SYNDROME, FOETAL EXPOSURE DURING PREGNANCY, IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME, SEROTONIN SYNDROME, ADRENAL INSUFFICIENCY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Gilead Sciences, Inc. in connection with COBICISTAT. Always verify the specific product and NDC with your pharmacist.